A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma
Conditions: Melanoma (Skin) Interventions: Dietary Supplement: C-PAN; Biological: Nivolumab; Biological: Ipilimumab Sponsors: University Health Network, Toronto Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
CARE1 Pragmatic Clinical Trial
Conditions: Metastatic Kidney Cancer; Metastatic Kidney Carcinoma Interventions: Drug: Nivolumab; Drug: Ipilimumab; Drug: Pembrolizumab; Drug: Cabozantinib; Drug: Axitinib; Drug: Lenvatinib Sponsors: Gustave Roussy, Cancer Campus, Grand Paris; European Commission; CRIS Cancer Foundation; National Cancer Institute, France; Rennes University Hospital; University Hospital, Essen; Fundaci ó Privada Institut d ' Investigaci ó Oncològica de Vall d ' Hebron; The Netherlands Cancer Institute; Servicio Madrile ño de Salud, Madrid, Spain; Hospital Universitario 12 de Octubre; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan...
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
Conditions: Non-Small Cell Lung Cancer; PDL1 Negative Non-Small Cell Lung Cancer (NSCLC) Interventions: Drug: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Pemetrexed; Drug: Nivolumab; Drug: Ipilimumab Sponsors: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
Conditions: Melanoma Interventions: Drug: Ipilimumab; Drug: Nivolumab Sponsors: University of Utah Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Conditions: Advanced Cancer; Advanced Solid Tumor; Melanoma; Metastasis; Pleural Mesothelioma; Renal Cell Carcinoma; MSI-High; Mismatch Repair Deficiency; Colorectal Cancer; Hepatocellular Carcinoma; Hepatocellular Cancer; Renal Cell Cancer; Kidney Cancer; Skin Cancer; Non Small Cell Lung Cancer; NSCLC; Anaplastic Lymphoma Kinase Genomic Tumor Aberrations; ALK Genomic Tumor Aberrations Interventions: Drug: Alintegimod; Drug: Ipilimumab; Drug: Nivolumab Sponsors: 7 Hills Pharma, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
XH001 Combination With Ipilimumab and Chemotherapy for Patients With Resected Pancreatic Cancer
Conditions: Pancreatic Cancer Interventions: Biological: XH001; Drug: Ipilimumab Injection; Drug: Chemotherapy Sponsors: Wu Wenming; NeoCura Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
Conditions: Advanced Renal Cell Carcinoma (aRCC) Interventions: Combination Product: Nivolumab + Ipilimumab combination therapy; Combination Product: Pembrolizumab + Lenvatinib combination therapy Sponsors: Bristol-Myers Squibb Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
Conditions: Metastatic Breast Cancer Interventions: Drug: Tiragolumab; Drug: Atezolizumab; Drug: Ipilimumab Sponsors: The Netherlands Cancer Institute; Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Early Stage Triple-Negative Breast Carcinoma; Locally Advanced Triple-Negative Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma; Prognostic Stage ...
Source: ClinicalTrials.gov - March 21, 2024 Category: Research Source Type: clinical trials
Biomarker Driven Patient Selection Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Conditions: Melanoma Stage III; Melanoma Stage IV; Advanced Melanoma; Melanoma Interventions: Drug: Nivolumab; Drug: Nivolumab + Relatlimab; Drug: Ipilimumab Sponsors: H. Lee Moffitt Cancer Center and Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials
Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients
Conditions: ICB-refractory Melanoma Interventions: Other: Prebiotic Food-Enriched Diet; Drug: Ipilimumab; Drug: Nivolumab Sponsors: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
Conditions: Melanoma Interventions: Drug: Ipilimumab; Drug: Nivolumab; Drug: Nivolumab Sponsors: The Netherlands Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
Conditions: Melanoma Brain Metastases Interventions: Drug: Bevacizumab; Drug: Ipilimumab; Drug: Nivolumab; Radiation: Hypofractionated stereotactic radiotherapy Sponsors: Melanoma and Skin Cancer Trials Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma
Conditions: Melanoma Interventions: Drug: Nivolumab +/- ipilimumab; Drug: Nivolumab Sponsors: Bristol-Myers Squibb Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects
Conditions: Healthy Male Volunteers Interventions: Drug: HLX13; Drug: CN-sourced ipilimumab; Drug: EU-sourced ipilimumab group; Drug: US-sourced ipilimumab group Sponsors: Shanghai Henlius Biotech Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 6, 2023 Category: Research Source Type: clinical trials
